Prioritization of screening programs for spinal muscular atrophy (SMA) will ensure early diagnosis across Canada and bring lasting impact to babies and caregivers MONTREAL – Novartis Pharmaceuticals Canada Inc. (Novartis) applauds the… Read More
RYBREVANT® plus LAZCLUZE™ is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinib Following Priority Review, approval is based on Phase 3 MARIPOSA results showing RYBREVANT® plus LAZCLUZE™ reduced… Read More
A $2.5 million donation from the Conconi Family Foundation helped to unlock the federal grant. Together, government and philanthropic support has helped to launch the new Biodevice Foundry at SBME—a… Read More
Monomeric form of GLP-1 drug preserved by DehydraTECH KELOWNA, BC – Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces positive findings from… Read More
TEPKINLY (epcoritamab) is the first and only subcutaneous bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R… Read More
